These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2737794)

  • 41. An adjusted two one-sided t-test for the assessment of bioequivalence with multiple doses.
    Wang W; Hsuan F; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):157-70. PubMed ID: 9056595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statistical aspects of comparative bioavailability trials.
    Westlake WJ
    Biometrics; 1979 Mar; 35(1):273-80. PubMed ID: 583027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax.
    el-Tahtawy AA; Jackson AJ; Ludden TM
    Pharm Res; 1995 Nov; 12(11):1634-41. PubMed ID: 8592662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishing bioequivalence of veterinary premixes (Type A medicated articles).
    Hunter RP; Lees P; Concordet D; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():53-63. PubMed ID: 22413792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioavailability and bioequivalence: focus on physiological factors and variability.
    Karalis V; Macheras P; Van Peer A; Shah VP
    Pharm Res; 2008 Aug; 25(8):1956-62. PubMed ID: 18551249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Open questions on bioequivalence: some problems and some solutions.
    Marzo A
    Pharmacol Res; 1999 Oct; 40(4):357-68. PubMed ID: 10527649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Striving for standards in bioequivalence assessment: a review.
    Schulz HU; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S1-6. PubMed ID: 1601528
    [No Abstract]   [Full Text] [Related]  

  • 49. Critical evaluation of thioridazine bioequivalence.
    Barone JA; Colaizzi JL
    Drug Intell Clin Pharm; 1985 Nov; 19(11):847-58. PubMed ID: 3905323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies.
    Blume HH; Midha KK
    J Pharm Sci; 1993 Nov; 82(11):1186-9. PubMed ID: 7904641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A spreadsheet program for simulation of bioequivalence and bioavailability studies.
    Abdallah HY; Ludden TM
    Comput Biol Med; 1995 May; 25(3):349-54. PubMed ID: 7554851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.
    Shah VP; Midha KK; Dighe S; McGilveray IJ; Skelly JP; Yacobi A; Layloff T; Viswanathan CT; Cook CE; McDowall RD
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):249-55. PubMed ID: 1823867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of rate of absorption in bioequivalence studies.
    Aarons L
    J Pharm Sci; 1987 Oct; 76(10):853-5. PubMed ID: 3430353
    [No Abstract]   [Full Text] [Related]  

  • 55. Open questions on bioequivalence: an updated reappraisal.
    Marzo A
    Curr Clin Pharmacol; 2007 May; 2(2):179-89. PubMed ID: 18690864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design.
    Dissanayake S
    Br J Clin Pharmacol; 2010 Mar; 69(3):238-44. PubMed ID: 20233194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioequivalence revisited.
    Sheiner LB
    Stat Med; 1992 Sep; 11(13):1777-88. PubMed ID: 1485060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Limitations of the MANOVA of statistical moments in bioequivalence trials of drugs with slow elimination rate: a study with spironolactone.
    Concheiro A; Llabres M; Martinez R; Vila JL
    Biopharm Drug Dispos; 1986; 7(3):253-64. PubMed ID: 3730525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of the 1993 Veterinary Drug Bioequivalence Workshop, held on March 29-31, 1993, in Rockville, Maryland.
    J Vet Pharmacol Ther; 1994 Apr; 17(2):85-119. PubMed ID: 7913728
    [No Abstract]   [Full Text] [Related]  

  • 60. Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification.
    Staack RF; Jordan G; Heinrich J
    Bioanalysis; 2012 Feb; 4(4):381-95. PubMed ID: 22394139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.